Lassie: The first-ever painless breath analyser for people with diabetes, a breakthrough in blood glucose monitoring

Informations projet

Lassie

N° de convention de subvention: 190162033

DOI

10.3030/190162033

Projet clôturé

Date de signature de la CE 18 Juillet 2022

Date de début 1 Août 2022

Date de fin 31 Decembre 2025

Financé au titre de

• The European Innovation Council (EIC)

Coût total

€ 8 710 500,00

Contribution de l’UE

€ 2 500 000,00

Coordonné par

BOYDSENSE
France

Periodic Reporting for period 2 - Lassie (Lassie: The first-ever painless breath analyser for people with diabetes, a breakthrough in blood glucose monitoring)

Période du rapport: 2023-11-01 au 2025-12-31

Résumé du contexte et des objectifs généraux du projet

Today, dogs are used to detect high and low blood glucose, cancers and are tested for coronavirus.
The new Lassie breath analyser BOYDSense will put the power of a dog’s nose into people’s hands and give them access to gentle health monitoring.
Lassie starts with diabetes as it is an immense burden for 40 million people in Europe. Current glucose monitoring technologies are underused because they are highly invasive, expensive, stigmatising and generate a lot of waste.
Lassie will transform this situation by making measurements painless, simple, discreet and cost-effective without any consumables.
Lassie is is a Breath Analysis Blood Glucose Monitoring Device which measures Volatile Organic Compounds (VOCs) in breath. The VOCs are detected by Gas Sensor Array and the corresponding Blood Glucose value is calculated.
Three clinical trials have been performed allowing to validate the embeded algorithm for blood glucose value calculatation within current accuracy standard. These trials has also allowed to better understand the breathprint VOCs associated to the blood glucose.
The results of the breath analysis can be shared across patient and healthcare professionals via third party Mobile App platforms.
As a result, Lassie users will test earlier in the disease and more frequently, leading to better diabetes management and significant cost savings.
EIC Accelerator grant has allowed BOYDSense to finalise our product development and validation.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

BOYDSense is developing a small and discrete pocket-size Lassie™ breath analyser. Several times per minute, there is an incredible amount of information released into the air by our bodies. Lassie captures this information to reinvent care.
Lassie is a breakthrough, non-invasive medical device for people with diabetes and prediabetes. Its analysis will take less than 2 minutes to measure Volatile Organic Compounds (VOCs) in exhaled breath, providing information about current glucose level that was previously available only through blood and interstitial fluid testing.
Lassie is currently tested in clinical trials to evaluate and optimise its performance. NCT05207020 is just finalised with good results on device performance. The patients show high enthusiasm in the study and high expectations for the future system.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Lassie will replace the existing, invasive and painful finger-pricking Blood Glucose Meters (BGM) to become a new standard of medical care in daily diabetes management. We also expect that Lassie will become an alternative to Continuous Glucose Monitoring (CGM) for people with diabetes who do not need to wear a patch 24/7. Our combination of non-invasive technology and telemedicine capabilities enables unseen ease of use and quality of care at an affordable cost.
The patients show high expectations for the expected benefits of a breath-based blood glucose monitoring system, not only improving quality of life, but has a very positive impact on the frequency and quality of self-monitoring.
BOYDSense is currently seeking for new investors to join current, leading investors in our Serie A.